Publications, 2001

Department of Oncology, Lund University Hospital, Lund

  1. Akervall J, Brun E, Dictor M, and Wennerberg J: Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck – preliminary report. Acta Oncol 2001; 40(4): 505-511.
  1. Andersson C, Lydrup M-L, Fernö M, Idvall I, Gustafsson J-Å, and Nilsson B-O: Immunocytochemical demonstration of oestrogen receptor beta in blood vessels of the female rat. J Endocrinol 2001; 169 (2): 241-247.
  1. Areberg J, Wennerberg J, Johnsson A, Norrgren K, and Mattsson S: Antitumor effect of radioactive cisplatin (191Pt) on nude mice. Int J Radiat Oncol Biol Phys 2001; 49 (3): 827-832.
  1. Arver B, Borg Å, and Lindblom A: First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm. Genet Test 2001; 5 (1): 1-8.
  1. Bagwell CB, Clark GM, Spyratos F, Chassevent A, Bendahl P-O, Stål O, Killan-

der D, Jourdan ML, Romain S, Hunsberger B, and Baldetorp B: Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Cytometry (Comm Clin Cyt) 2001; 46 (3): 121-135.

  1. Bagwell CB, Clark GM, Spyratos F, Chassevent A, Bendahl P-O, Stål O, Killan-

der D, Jourdan M-L, Romain S, Hunsberger B, Wright S, and Baldetorp B: DNA and cell cycle analysis as prognostic indicators in breast tumors revisited, in Clin Lab Med,New Applications of Flow Cytometry(McCoy JP & Keren DF, eds) 2001; 21 (4): 875-895.

  1. Barkardottir RB, Sarantaus L, Asaron A, Vehmanen P, Bendahl P-O, Kainu T, Syrjakoski K, Krane R, Huusko P, Pyrhonen S, Holli K, Kallioniemi OP, Egilsson V, Kere J, and Nevanlinna M: Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. Eur J Hum Genet 2001; 9(10): 773-779.
  1. Bergthorsson J, Ejlertsen B, Olsen JH, Borg Å, Nielsen KV, Barkardottir RB, Klausen S, Mouridsen HT, Winther K, Fenger K, Niebuhr A, Harboe TL, and Niebuhr E: BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J Med Genet 2001; 38 (6): 361-368.
  1. Borg Å: Hereditary prostate cancer: A new piece of the puzzle. An eagerly awaited prostate cancer susceptibility gene has been announced. But does the candidate live up to expectations? Nat Med 2001; 7 (2): 153-155.
  1. Borg Å: Molecular and pathological characterization of inherited breast cancer. Semin Cancer Biol 2001; 11 (5): 375-385.

Febr 2002/MF

  1. Brun E, Zätterström U, Kjellén E, Wahlberg P, Willén R, Brun A, Perfekt R, and Tennvall J: Prognostic value of histopathological response to radiotherappy and microvessel density in oral squamous cell carcinomas. Acta Oncol 2001; 40 (4): 491-496.
  1. Carlsson C, Killander D, Omne-Pontén M, and Sätterlund-Larsson UB: Voluntary associations for cancer patients in Sweden: Supportive activities. Support Care Cancer 2001; 9 (8): 581-590.
  1. Eker C, Rydell R, Svanberg K, and Andersson-Engels S: Multivariate analysis of laryngeal fluorescence spectra recorded in vivo. Lasers Surg Med 2001; 28 (3): 259-266.
  1. Engellau J, Åkerman M, Anderson H, Domanski HA, Rambech E, Alvegård TA, and Nilbert M: Tissue-microarray technique in soft tissue sarcoma: Immunohistochemical Ki-67 expression in malignant fibrous histiocytoma. Appl Immunohistochem Mol Morphol 2001; 9 (4): 358-363.
  1. Esteller M, Fraga M, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barriére C, Bignon YJ, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal MJ, Rodriguez R, Capella G, Angel Peinado M, Borg Å, Aaltonen LA, Ponder BA, Baylin SB, and Herman JG: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10: 3001-3007.
  1. Fernebro E, Madsen RR, Fernö M, Brünner N, Bendahl P-O, Christensen IJ, Johnson A, and Nilbert M: Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001; 37 (4): 486-491.
  1. Fredstorp-Lidebring M, Bendahl P-O, Brünner N, Casslén B, Högberg T, Långström-Einarsson E, Willén R, and Fernö M: Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur J Cancer 2001; 37 (18): 2339-2348.
  1. Gentile M, Wiman A, Thorstenson S, Loman N, Borg Å, and Wingren S: Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast cancer. Int J Cancer 2001; 92 (2): 208-213.
  1. Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg Å, Fernö M, Peter-son C, and Meltzer PS: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61 (16): 5979-5984.
  1. Grönberg H, Ahman AK, Emanuelsson M, Bergh A, Damber JE, and Borg Å: BRCA2 mutation in a family with hereditary prostate cancer. Genes Chromosomes Cancer 2001; 30 (3): 299-301.

  1. Hakamies-Blomqvist L, Luoma M-L, Sjöström J, Pluzanska A, Sjödin M, Mourid-sen H, Östenstad B, Mjaaland I, Lönn S, Bergh J, Malmström P-O, and Blom-

qvist C: Timing of quality of life assessments as a source of error in oncological

trials. J Adv Nurs 2001; 35:709-716.

  1. Hardell L, Eriksson M, Lindström G, van Bavel B, Linde A, Carlberg M, and Liljegren G: Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma. Leukemia and Lymphoma 2001; 42(4): 619-629.
  1. Hashemi J, Bendahl P-O, Sandberg T, Platz A, Linder S, Stierner U, Olsson H, Ingvar C, Hansson J, and Borg Å: Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families. Genes Chromosomes Cancer 2001; 31 (2): 107-116.
  1. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Wilfond B, Sauter G, Kallioniemi O-P, Borg Å, and Trent J: Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344 (8): 539-548.
  1. Hedenfalk I, Simon R, and Trent J: Correspondence: Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 2029.
  1. Idvall I, Andersson C, Fallenius G, Ingvar C, Ringberg A, Strand C, Åkerman M, and Fernö M: Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening. Acta Oncol 2001; 40 (5): 653-659.
  1. Jerkeman M, Kaasa S, Hjermstad M, Kvaløy S, and Cavallin-Ståhl E: Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol 2001; 18 (1):

85-94.

  1. Jernström H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, and Narod SA: Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: Implications for premenopausal breast cancer risk. Mol Genet Metab 2001; 72 (2): 144-154.
  1. Jernström H, Vesprini D, Bradlow HL, and Narod SA: Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 2001; 93 (7): 554-555.
  1. Jernström H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, and Pollak M: Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001; 10 (4): 377-384.
  1. Johnsson A, Byrne P, de Bruin R, Weiner D, Wong J, and Los G. Identification of gene clusters differentially expressed during the cellular injury responses to cisplatin. Br J Cancer 2001; 85: 1206-1210.
  1. Kaerlev L, Stubbe Teglbjaerg P, Sabroe S, Kolstad HA, Ahrens W, Eriksson M, Guénel P, Hardell L, Launoy G, Merler E, Merletti F, and Stang A: Medical risk factors for small bowel adenocarcinoma with focus on Crohn disease: a European population-based case-control study. Scand J Gastroenterol 2001; 36: 641-646.
  1. Kinhult S, Albertsson M, Eskilsson J, and Cwikiel M: Antithrombotic treatment in protection against thrombogenic effects of 5-Fluorouracil on vascular endothelium: A scanning microscopy evaluation. Scanning 2001; 23 (1): 1-8.
  1. Koul A, Loman N, Malander S, Borg Å, and Ridderheim M: Two BRCA-1 positive epithelial ovarian tumors with metastases to the central nervous system: A case report. Gynecol Oncol 2001; 80 (3): 399-402.
  1. Lai J, Vesprini D, Chu W, Jernström H, and Narod SA: CYP gene polymorphisms and early menarche. Mol Gen Metab 2001; 74 (4): 449-457.
  1. Loman N, Johannsson O, Kristoffersson U, Olsson H, and Borg Å: Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 2001; 93 (16): 1215-1223.
  1. Malmström P, Bendahl P-O, Boiesen P, Brünner N, Idvall I, and Fernö M: S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham prognostic index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001; 19 (7): 2010-2019.
  1. Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, and Longo G: Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84 (3): 303-307.
  1. Måsbäck A, Olsson H, Westerdahl J, Ingvar C, and Jonsson N: Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001; 11 (5): 435-445.
  1. Möller P, Heimdal K, Apold J, Fredriksen Å, Borg Å, Hovig E, Hagen A, Hagen B, Pedersen JC, and Maehle L: The Norwegian Inherited Breast Cancer Group, The Norwegian Inherited Ovarian Cancer Group. Genetic epidemiology of familial breast cancer in Norway. Eur J Cancer 2001; 37: 2428-2438.
  1. Möller P, Borg Å, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, and Maehle L: The BRCA1 syndrome and other subgroups of inherited breast and/or ovarian cancer in a prospective population-based series. Eur J Cancer 2001; 37: 1027-1032.
  1. Olsson H: A hypothesis about tumour development and the clinical features of hereditary breast cancers. Eur J Cancer 2001; 37 (16): 2023-2029.
  1. Olsson H, Bladström A, Ingvar C, and Möller TR: A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 2001; 85 (5): 674-677.
  1. Pejovic T, Koul A, Olsen D, Zheng W, and Chambers JT: No BRCA1 germline mutation in a family with uterine papillary carcinoma: Case report. Eur J Gyn

Cancer 2001; 22(5): 336-338.

  1. Relander T, Brun A, Hawley RG, Karlsson S, and Richter J: Retroviral transduction of human CD34+ cells on fibronectin fragment CH-296 is inhibited by high concentrations of vector containing medium. J Gene Med 2001; 3 (3): 207-218.
  1. Rennstam K, Baldetorp B, Kytölä S, Tanner M, and Isola J: Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 2001; 61 (3): 1214-1219.
  1. Ringberg A, Anagnostaki L, Anderson H, Idvall I, and Fernö M: Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 2001; 37 (12): 1514-1522.
  1. Romain S, Bendahl P-O, Guirou O, Malmström P, Martin PM, and Fernö M: DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients. Int J Cancer 2001; 95 (1): 56-61.
  1. Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Fernö M, Baldetorp B, and Parwaresch R: Concurrent overexpression of p53 and c-erbB-2 correlates with acce-lerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol 2001; 32 (3): 311-319.
  1. Salahshor S, Haixin L, Huo H, Kristensen VN, Loman N, Sjöberg-Margolin S, Børresen-Dale A-L, Borg Å, Vorechovsky I, and Lindblom A: Low frequency of E-cadherin alterations in familial breast cancer. Breast Cancer Res 2001; 3 (3):

199-207.

51.Soto Thompson M, Gustafsson L, Pålsson S, Bendsoe N, Stenberg M, af Klinteberg C, Andersson-Engels S, and Svanberg K: Photodynamic therapy and diagnostic measurements of basal cell carcinomas using esterified and non esterified 5-aminolevulinic acid. J Porphyrins Phthalocyanines 2001; 5:147-153.

  1. Staff S, Isola JJ, Johannsson O, Borg Å, and Tanner MM. Frequent somatic loss

of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers, and vice versa. Br J Cancer 2001; 85: 1201-1205.

53.Stockeld D, Tennvall J, Wagenius G, Albertsson M, Backman L, Brodin O,

Cwikiel M, Granström L, Gustafsson G, Gustavsson S, Hambraeus G, Lewen-

sohn R, Sjöstedt S, Strander H, Åberg B, and Fagerberg J: A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus. Acta Oncol 2001; 40 (5): 566-573.

54.Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum-Nielsen K, Gerdes AM, Møller P, Kristoffersson U, Olsson H, Borg Å, and Monterio AN: Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 2001; 10 (4): 353-360.

55.Wang I, Bendsoe N, af Klintenberg C, Enejder AMK, Andersson-Engels S, Svanberg S,and Svanberg K: Photodynamic therapy versus cryosurgery of basal cell carcinomas: results of a phases III clinical trial. Br J Dermatol 2001; 144 (4): 832-840.

56.Åkervall J, Brun E, Dictor M, and Wennerberg J: Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck. Acta Oncol 2001; 40(4): 505-512.

  1. Ösby E, Taube A, Cavallin-Ståhl E, Hagberg H, and Björkholm M: Reproducibility of tumour response evaluation in patients with high-grade malignant non-Hodgkin´s lymphoma. Med Oncol 2001; 18 (2):137-140.

1